1. Cell Cycle/DNA Damage
    NF-κB
    Membrane Transporter/Ion Channel
    Autophagy
  2. PPAR
    TRP Channel
    Autophagy

Rosiglitazone (Synonyms: BRL49653)

Cat. No.: HY-17386 Purity: 99.46%
Data Sheet SDS Handling Instructions

Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, and is a blocker of TRPM2 and TRPM3 channels.

For research use only. We do not sell to patients.
Rosiglitazone Chemical Structure

Rosiglitazone Chemical Structure

CAS No. : 122320-73-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
50 mg $50 In-stock
200 mg $150 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Rosiglitazone:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, and is a blocker of TRPM2 and TRPM3 channels.

IC50 & Target

TRPM2 and TRPM3 blocker[1]
PPAR agonist[2]

In Vitro

TRPM2 is unaffected by Rosiglitazone at concentrations up to 10 μM but is inhibited completely at higher concentrations (IC50~22.5 μM). TRPC5 is strongly stimulated by Rosiglitazone at concentrations of 10 μM and greater (EC50~30 μM). Low concentrations of Rosiglitazone (0.1-1 μM) cause about 20 % inhibition of TRPM3. Higher concentrations of Rosiglitazone cause stronger and complete TRPM3 inhibition with IC50 values of 9.5 μM and 4.6 μM against nifedipine- and PregS-evoked activity[1]. Rosiglitazone is a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, which is an anti-diabetic agent against type 2 diabetes[2].

In Vivo

Rosiglitazone prevents Endotoxin lethality by attenuating HMGB1 release. BALB/c mice (n=10-11 per group) are injected with a single dose of Rosiglitazone (10 mg/kg, i.p.) with or without GW9662 (1 mg/kg, i.p.), followed 30 min later by a lethal infusion of Endotoxin (LPS, 10 mg/kg, i.p.)[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01706211 National Taiwan University Hospital Diabetes Mellitus Non Insulin Dependent Oral Agent Therapy October 1998 Phase 3
NCT00432679 GlaxoSmithKline Diabetes Mellitus, Type 2 May 2006 Phase 3
NCT01706211 National Taiwan University Hospital Diabetes Mellitus Non Insulin Dependent Oral Agent Therapy October 1998 Phase 3
NCT00432679 GlaxoSmithKline Diabetes Mellitus, Type 2 May 2006 Phase 3
NCT00182052 Massachusetts General Hospital|Dana-Farber Cancer Institute Adenocarcinoma of the Prostate|Prostate Cancer September 2000 Phase 3
NCT00785213 Mutual Pharmaceutical Company, Inc.|Cetero Research, San Antonio Healthy September 2008 Phase 1
NCT00065065 James Lewis|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|GlaxoSmithKline|University of Pennsylvania Ulcerative Colitis|Inflammatory Bowel Disease September 2002 Phase 2
NCT01100619 Exelixis Papillary Thyroid Cancer|Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Renal Cell Carcinoma April 2010 Phase 1
NCT00486187 Dr. Milan Gupta|GlaxoSmithKline|Canadian Collaborative Research Network Type 2 Diabetes Mellitus April 2006
NCT00405015 Radboud University|GlaxoSmithKline Ischemia-Reperfusion Injury|The Metabolic Syndrome April 2007 Phase 2
NCT00169832 Laval University|GlaxoSmithKline Diabetes|Coronary Artery Bypass Grafting June 2003 Phase 3
NCT00242593 University of Washington|National Institute on Aging (NIA)|GlaxoSmithKline Mild Cognitive Impairment June 2006 Phase 2
NCT02694874 Centro de Investigacao em Saude de Manhica|University Health Network, Toronto|Barcelona Institute for Global Health Malaria February 2016
NCT00746174 University of Texas Southwestern Medical Center|GlaxoSmithKline Insulin Sensitivity February 2004 Phase 4
NCT00207402 Brooke Army Medical Center|InterMune Hepatitis C October 2005 Phase 4
NCT00231387 GlaxoSmithKline Non-insulin-dependent Diabetes Mellitus September 2002 Phase 3
NCT01577095 China Medical University Hospital Type 2 Diabetes Mellitus With Features of Insulin Resistance April 2006 Phase 2
NCT00819910 Ahmad Slim|GlaxoSmithKline|Brooke Army Medical Center Hypertriglyceridemia in Type 4 Hyperlipidemia|Non Diabetic Subjects With Normoglycemia September 2008 Phase 4
NCT00367744 National Institute of Allergy and Infectious Diseases (NIAID)|GlaxoSmithKline HIV Infections July 2006 Phase 2
NCT00004180 Dana-Farber Cancer Institute|National Cancer Institute (NCI) Sarcoma October 1999 Phase 2
NCT02526615 Turku University Hospital|SmithKline Beecham Insulin Sensitivity|Type 2 Diabetes October 2000 Phase 4
NCT00369174 National Cancer Institute (NCI) Oral Leukoplakia June 2006 Phase 2
NCT00616642 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors October 2006 Phase 2
NCT00381238 GlaxoSmithKline Alzheimer's Disease June 20, 2006 Phase 2
NCT00424762 University of Texas Southwestern Medical Center|GlaxoSmithKline|Biosite Diabetes Mellitus, Type 2 February 2005 Phase 4
NCT01406704 Seoul St. Mary's Hospital|GlaxoSmithKline NASH (Non-alcoholic Steato-hepatitis) January 2004 Phase 4
NCT00285805 Radboud University Insulin Resistance February 2006
NCT01150981 University of Massachusetts, Worcester|GlaxoSmithKline Metabolic Syndrome|Insulin Resistance November 2006 Phase 2
NCT00609362 University of Aarhus Change in Bone Mineral Density|Change in Bone Marrow Fat Content January 2008 Phase 2
NCT00337350 Massachusetts General Hospital|National Alliance for Research on Schizophrenia and Depression|Stanley Medical Research Institute Schizophrenia September 2003 Phase 4
NCT00614874 Creighton University Asthma December 2008 Phase 2
NCT00290394 Baskent University Diabetes Mellitus, Type 2 March 2004 Phase 4
NCT01195259 GlaxoSmithKline Diabetes Mellitus, Type 2 October 2009
NCT00733174 Denver Research Institute|GlaxoSmithKline Impaired Glucose Tolerance March 2004 Phase 4
NCT00274495 Beth Israel Medical Center Chronic Hepatitis C Infection|Fatty Liver January 2006 Phase 4
NCT00306176 Aristotle University Of Thessaloniki|University of Athens Type II Diabetes Mellitus January 2005 Phase 4
NCT00413335 Yale University Obesity|Impaired Glucose Tolerance|Type 2 Diabetes Mellitus November 2005
NCT00135330 AstraZeneca|Eli Lilly and Company Diabetes Mellitus, Type 2 October 2005 Phase 3
NCT00500955 GlaxoSmithKline Diabetes Mellitus, Type 2 April 2000 Phase 3
NCT01415128 VIVUS, Inc. Erectile Dysfunction April 2010 Phase 1
NCT00333723 GlaxoSmithKline Diabetes Mellitus, Type 2 July 2000 Phase 4
NCT00242619 Stanford University Depression|Bipolar Disorder|Insulin Resistance July 2007
NCT00523913 GlaxoSmithKline Diabetes Mellitus, Type 2 November 2005 Phase 3
NCT00349427 GlaxoSmithKline Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2 October 2005 Phase 3
NCT00265148 GlaxoSmithKline Alzheimer's Disease May 2004 Phase 2
NCT00612066 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Cushing's Disease April 2007 Phase 2
NCT00119496 University of Glasgow|GlaxoSmithKline|Chest, Heart and Stroke Association Scotland|Chief Scientist Office of the Scottish Government Asthma July 2005 Phase 2|Phase 3
NCT01453049 GlaxoSmithKline Diabetes Mellitus, Type 2 April 2010 Phase 3
NCT00688207 GlaxoSmithKline Alzheimer's Disease April 2008 Phase 1
NCT00279045 GlaxoSmithKline Diabetes Mellitus, Type 2 January 2000 Phase 3
NCT00550420 GlaxoSmithKline Alzheimer's Disease October 2007 Phase 3
NCT00178841 Vanderbilt University Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome June 2005 Phase 2
NCT00428090 GlaxoSmithKline Alzheimer's Disease February 27, 2007 Phase 3
NCT00331487 Takeda|Eli Lilly and Company Diabetes Mellitus September 2000 Phase 3
NCT00318656 GlaxoSmithKline Non-Insulin-Dependent Diabetes Mellitus November 2005 Phase 4
NCT00490568 GlaxoSmithKline Alzheimer's Disease August 2007 Phase 3
NCT01209143 Genentech, Inc. Solid Cancers November 2010 Phase 1
NCT00194896 University of Washington|Seattle Institute for Biomedical and Clinical Research|GlaxoSmithKline Type 2 Diabetes Mellitus February 2000
NCT01872780 Inje University Healthy August 2008 Phase 1
NCT00285142 University Hospital, Montpellier Healthy June 2004
NCT01574820 National Cheng-Kung University Hospital Prediabetes|Coronary Artery Disease|Insulin Resistance|Glucose Intolerance November 2006 Phase 3
NCT00123227 Royal Brompton & Harefield NHS Foundation Trust|GlaxoSmithKline|CORDA, The Heart Charity Diabetes Mellitus, Type 2|Vascular Diseases|Hypertension October 2002 Phase 3
NCT00306644 GlaxoSmithKline Diabetes Mellitus, Type 2 May 2002 Phase 4
NCT00324675 Technische Universität Dresden Type 2 Diabetes|Overt Diabetic Nephropathy August 2006
NCT01332370 GlaxoSmithKline Diabetes Mellitus, Type 2 December 2009
NCT00499707 GlaxoSmithKline Diabetes Mellitus, Type 2 October 2003 Phase 3
NCT00484419 Daiichi Sankyo Inc. Type 2 Diabetes|Hyperlipidemia May 2007 Phase 3
NCT00123643 St. Paul Heart Clinic|GlaxoSmithKline Type 2 Diabetes Mellitus May 2003 Phase 4
NCT00130286 Weill Medical College of Cornell University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) HIV-Associated Lipodystrophy Syndrome|Insulin Resistance|HIV Infections|Metabolic Syndrome X|Body Weight Changes March 2005 Phase 1|Phase 2
NCT00675740 University of Leipzig Impaired Glucose Tolerance January 2004 Phase 4
NCT00379769 GlaxoSmithKline Diabetes Mellitus, Type 2 April 2001 Phase 3
NCT00522470 Baskent University Type 2 Diabetes Mellitus|Obesity Phase 4
NCT00452166 Leiden University Medical Center Chronic Kidney Disease|Insulin Resistance April 2007 Phase 3
NCT00364221 University of Colorado, Denver Metabolic Syndrome|Insulin Resistance November 2004 Phase 4
NCT00115661 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Berlex Foundation Endometriosis July 2005 Phase 2
NCT00098852 University of California, San Francisco|National Cancer Institute (NCI) Head and Neck Cancer October 2004 Phase 2
NCT00309309 Mario Negri Institute for Pharmacological Research Kidney Transplant April 2005 Phase 2
NCT00314561 Korea University Anam Hospital Metabolic Syndrome May 2006 Phase 4
NCT00348309 GlaxoSmithKline Alzheimer's Disease July 2006
NCT00372086 The University of New South Wales|Sydney Children's Network|National Health and Medical Research Council, Australia|Novo Nordisk A/S Type 1 Diabetes|Puberty: >Tanner 2 Breast Development or Testis >4ml August 2003 Phase 4
NCT00492700 Association pour la Recherche sur les Maladies Hépatiques Virales Non Alcoholic Steatohepatitis January 2003 Phase 2
NCT00225225 Stanford University|GlaxoSmithKline Diabetes Mellitus, Type 2 October 2002
NCT00166803 National Taiwan University Hospital|National Science Council, Taiwan Diabetes Mellitus, Atherosclerosis June 2005
NCT00367055 GlaxoSmithKline Type 2 Diabetes Mellitus October 2004 Phase 4
NCT00953498 Centre Hospitalier Universitaire Dijon Type 2 Diabetes October 2007 Phase 4
NCT00154011 Technische Universität Dresden Healthy Subjects September 2005
NCT00169923 Leiden University Medical Center Chronic Kidney Disease|Inflammation April 2007 Phase 2|Phase 3
NCT00831129 University of Chicago|GlaxoSmithKline Pre-diabetes September 2006 Phase 2|Phase 3
NCT00116831 GlaxoSmithKline Atherosclerosis January 2005 Phase 3
NCT00143624 University of British Columbia Atherosclerosis|HIV Infections June 2003
NCT00300911 Baskent University Diabetes Mellitus, Type 2 December 2005 Phase 4
NCT00567593 James Lewis|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania Inflammatory Bowel Disease October 2007 Phase 4
NCT00149383 Mahidol University|McLaughlin-Rotman Center for Global Health, University of Toronto Falciparum Malaria December 2004 Phase 1|Phase 2
NCT00379600 GlaxoSmithKline Arthritis, Rheumatoid November 2004 Phase 2
NCT00329225 GlaxoSmithKline Diabetes Mellitus, Type 2 September 2002 Phase 4
NCT00186537 Stanford University|Abbott Insulin Resistance|Hypertriglyceridemia September 2003
NCT00140647 Gerstein, Hertzel, MD|Heart and Stroke Foundation of Ontario Atherosclerosis|Impaired Glucose Tolerance|Isolated Impaired Fasting Glucose|Cardiovascular Disease July 2001 Phase 3
NCT00095654 Gerstein, Hertzel, MD|Canadian Institutes of Health Research (CIHR)|Aventis Pharmaceuticals|GlaxoSmithKline|King Pharmaceuticals is now a wholly owned subsidiary of Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer Impaired Glucose Tolerance|Cardiovascular Disease|Glucose Metabolism Disorders July 2001 Phase 3
NCT00297063 GlaxoSmithKline Diabetes Mellitus, Type 2 January 2006 Phase 3
NCT00549874 University of Michigan|GlaxoSmithKline Type 2 Diabetes February 2002
NCT01088594 Solvay Pharmaceuticals Type 2 Diabetes Mellitus February 2010 Phase 1
NCT00025753 National Center for Research Resources (NCRR)|The Campbell Foundation HIV Infections|Insulin Resistance
NCT00015691 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Lipodystrophy|Hyperinsulinemia
NCT00306696 GlaxoSmithKline Diabetes Mellitus October 2002 Phase 4
NCT00501020 GlaxoSmithKline Diabetes Mellitus, Type 2 April 2001 Phase 4
NCT00282945 Pfizer Type 2 Diabetes Mellitus January 2006
NCT00618072 New York Medical College|Albert Einstein College of Medicine, Inc.|University of Tennessee Hyperinsulinemia|Insulin Resistance|Obesity January 2008 Phase 2
NCT00225342 University of Glasgow|GlaxoSmithKline Angina Pectoris|Diabetes Mellitus, Type 2 Phase 4
NCT00481429 Imperial College London|GlaxoSmithKline Diabetes Mellitus, Type 2 May 2007
NCT00203632 University of Calgary|GlaxoSmithKline Diabetes Mellitus September 2003 Phase 3
NCT00362726 Bristol-Myers Squibb HIV Infections September 2006 Phase 1
NCT00571506 University of Arkansas Diabetes Mellitus, Type 2|Vascular Diseases May 2004 Phase 4
NCT00361868 Solvay Pharmaceuticals Dyslipidemia|Glucose Metabolism Disorder June 2006 Phase 3
NCT00240604 Hadassah Medical Organization Glucose Intolerance April 2005 Phase 3
NCT00264251 St. Luke's-Roosevelt Hospital Center HIV Infections|Insulin Resistance|Obesity July 2005
NCT00334568 GlaxoSmithKline Alzheimer's Disease December 2004 Phase 2
NCT00348140 GlaxoSmithKline Alzheimer's Disease July 2006 Phase 3
NCT00422955 GlaxoSmithKline Neuropathy, Diabetic November 2003 Phase 3
NCT00640224 Children's Hospital of Pittsburgh|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Polycystic Ovary Syndrome March 2005 Phase 4
NCT00551564 GlaxoSmithKline Diabetes Mellitus, Type 2 July 2007 Phase 1
NCT00995995 GlaxoSmithKline Diabetes Mellitus, Type 2 October 2008
NCT01402076 Vanda Pharmaceuticals Healthy Volunteers August 2011 Phase 1
NCT00304993 Foundation Research, Florida|GlaxoSmithKline|Kos Pharmaceuticals|Abbott Metabolic Syndrome X|Insulin Resistance January 2001 Phase 4
NCT00370305 Charite University, Berlin, Germany Metabolic Syndrome|Impaired Glucose Tolerance May 2004 Phase 2
NCT00110851 Wellstat Therapeutics Type 2 Diabetes Mellitus April 2005 Phase 2
NCT01294553 GlaxoSmithKline Diabetes Mellitus, Type 2 June 2004
NCT00409097 VU University Medical Center Critical Illness|Multiple Organ Failure April 2006 Phase 3
NCT00501488 Central South University Diabetes Mellitus March 2006
NCT00006493 National Center for Research Resources (NCRR) HIV Infections|Hyperlipidemia Phase 2
NCT00121953 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Endometriosis July 2005 Phase 2|Phase 3
NCT00084578 Fox Chase Cancer Center|National Cancer Institute (NCI) Bladder Cancer March 2004
NCT00440375 Baskent University Type 2 Diabetes Mellitus|Obesity|Menopause June 2005 Phase 4
NCT00225355 University of Glasgow|British Heart Foundation|GlaxoSmithKline Angina Pectoris|Metabolic Syndrome X February 2006 Phase 4
NCT00733785 GlaxoSmithKline Alzheimer's Disease August 13, 2008 Phase 1
NCT00465296 Medstar Health Research Institute|GlaxoSmithKline Metabolic Syndrome January 2006 Phase 3
NCT00044460 GlaxoSmithKline Diabetes Mellitus, Type 2 May 2002 Phase 4
NCT00064727 National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Congestive Heart Failure July 9, 2003 Phase 2
NCT00679939 GlaxoSmithKline Diabetes Mellitus, Type 2 April 21, 2008 Phase 4
NCT00811356 GlaxoSmithKline Malaria December 2008 Phase 1
NCT01019356 Jean-Patrice Baillargeon|Canadian Institutes of Health Research (CIHR)|Université de Sherbrooke Polycystic Ovary Syndrome August 2006
NCT00466713 Stanford University Dilated Cardiomyopathy March 2007
NCT00399711 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 November 2006 Phase 3
NCT00309660 Herlev Hospital Ulcerative Colitis November 2005 Phase 1|Phase 2
NCT00489229 University of Science Malaysia|Ministry of Health, Malaysia Diabetes|Impaired Glucose Tolerance October 2002 Phase 3
NCT00358124 Sanofi Type 2 Diabetes Mellitus January 2001 Phase 4
NCT01287598 Bayer Neoplasms August 2, 2011 Phase 1
NCT00116922 Samuel Lunenfeld Research Institute, Mount Sinai Hospital|University of Western Ontario, Canada Impaired Glucose Tolerance|Diabetes June 2004 Phase 3
NCT00067951 GlaxoSmithKline Diabetes Mellitus, Type 2 October 2003 Phase 3
NCT00333151 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 May 2006 Phase 3
NCT00318422 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 May 2006 Phase 3
NCT00348712 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 October 30, 2006 Phase 3
NCT00343980 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 October 10, 2006 Phase 3
NCT00483392 University Medical Centre Ljubljana Insulin Resistance
NCT00541775 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus June 2006 Phase 3
NCT00607945 Ohio State University|National Center for Complementary and Integrative Health (NCCIH)|GlaxoSmithKline|Loders Croklaan|LifeScan Type 2 Diabetes Mellitus January 2008 Phase 1
NCT00427154 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 January 10, 2007 Phase 3
NCT01332071 GlaxoSmithKline Diabetes Mellitus, Type 2 November 24, 2009 Phase 1
NCT00256646 VA Office of Research and Development|American Diabetes Association Type 2 Diabetes Mellitus June 2007
NCT00738023 Emory University|GlaxoSmithKline Type 2 Diabetes|Hypertension March 2004 Phase 4
NCT00879970 GlaxoSmithKline|Academic Research Collaborator: Population Health Research Institute / Hamilton Health Diabetes Mellitus, Type 2 May 2009 Phase 4
NCT00252499 VA Office of Research and Development Fatty Liver|Insulin Resistance October 2005
NCT00069836 GlaxoSmithKline Diabetes Mellitus, Type 2 October 2003 Phase 3
NCT00081328 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diabetes Mellitus, Type II May 2004 Phase 3
NCT00193648 Northwell Health|University of North Carolina|The Cleveland Clinic Focal Glomerulosclerosis July 2005 Phase 1
NCT00516880 Hospital Authority, Hong Kong Chronic Disease|Kidney Diseases|Cardiovascular Diseases March 2006
NCT00018382 VA Office of Research and Development Alzheimer Disease October 1999 Phase 2
NCT00373178 Aristotle University Of Thessaloniki|University of Athens Type 2 Diabetes Mellitus January 2005 Phase 4
NCT00032487 VA Office of Research and Development|National Eye Institute (NEI)|SmithKline Beecham Type 2 Diabetes Mellitus December 1, 2000 Phase 3
NCT00241605 GlaxoSmithKline Diabetes Mellitus, Type 2 June 2003 Phase 4
NCT00121966 Odense University Hospital Type 2 Diabetes Mellitus January 2003 Phase 4
NCT00039663 National Institutes of Health Clinical Center (CC) HIV Infections May 2002 Phase 1
NCT00350779 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus June 12, 2006 Phase 3
NCT00443170 GlaxoSmithKline Healthy Subjects|Anaemia November 2006 Phase 1
NCT00692510 AstraZeneca Metabolism|Alzheimer's Disease November 2007 Phase 1
NCT00232362 Texas Tech University Health Sciences Center Type 2 Diabetes Mellitus June 2007 Phase 1
NCT00636766 Aristotle University Of Thessaloniki Carotid Atherosclerosis|Stroke|Type 2 Diabetes|Metabolic Syndrome September 2005
NCT00680745 AstraZeneca|Bristol-Myers Squibb Type 2 Diabetes April 2008 Phase 3
NCT00295633 AstraZeneca Diabetes Mellitus, Type 2 March 2006 Phase 3
NCT00015626 National Center for Research Resources (NCRR) Insulin Resistance|Diabetes Mellitus Phase 2
NCT00964106 GlaxoSmithKline Drug Interactions August 26, 2009 Phase 1
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.7978 mL 13.9888 mL 27.9775 mL
5 mM 0.5596 mL 2.7978 mL 5.5955 mL
10 mM 0.2798 mL 1.3989 mL 2.7978 mL
Cell Assay
[2]

Rosiglitazone is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2].

Human neuroblastoma SH-SY5Y cells are maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 μg/mL Streptomycin and 100 U/mL Penicillin G. SH-SY5Y cells are transfected with the longest isoform of human tau (2N4R) tagged with GFP using lipofectamine. 24 hr after transfection, cells are treated with Rosiglitazone (10 μM, 50 μM) for 24 hr[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2][3]

Rosiglitazone is prepared in DMSO, and then diluted in 0.5% carboxymethyl cellulose in drinking water to maximize solubility.

Rats[2]
OLETF rats are divided randomly into two groups (n=6 or 7 animals per group) at 21 weeks of age. Rats are given standard rat food or rat food supplemented with 3 mg/kg/day Rosiglitazone for 27 weeks. Urinary glucose is monitored weekly using Diastix. Individual rats are diagnosed as diabetic when positive glycosuria is identified. C57BL6 mice are divided randomly into two groups (n=7 animals per group) at 10 weeks of age. Mice received a single intraperitoneal injection of 150 mg/kg of STZ in 0.5 M sodium citrate buffer and, after 3 days, 3 mg/kg of Rosiglitazone or vehicle are daily administered per os for 4 consecutive days. Mice with glycemia over 11 mM glucose are diagnosed as diabetic.
Mice[3]
BALB/c mice are randomly assigned to one of four groups: injection of LPS (10 mg/kg), injection of LPS (10 mg/kg) plus Rosiglitazone (10 mg/kg), injection of LPS (10 mg/kg) plus Rosiglitazone (10 mg/kg) plus GW9662 (1 mg/kg), or injection of GW9662 (1 mg/kg) alone. Another group of BALB/c mice are treated with Rosiglitazone (10 mg/mL) after LPS (10 mg/kg) infusion. Mortality is recorded for up to 2 weeks after LPS injection to ensure that no additional late deaths occurred. For measurement of plasma HMGB1 levels, BALB/c mice are subjected to sepsis by LPS injection in the presence or absence of Rosiglitazone. After 20 h, blood is collected, allowed to clot for 2 h at room temperature, and then centrifuged for 20 min at 1,500 g. The levels of circulating HMGB1 in serum are determined by Western blot analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

357.43

Formula

C₁₈H₁₉N₃O₃S

CAS No.

122320-73-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 180 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Rosiglitazone
Cat. No.:
HY-17386
Quantity: